Cannabidiol is under clinical development by Avecho Biotechnology and currently in Phase II for Insomnia. According to GlobalData, Phase II drugs for Insomnia have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cannabidiol overview
Cannabidiol is under development for the treatment of pain reduction in osteoarthritis of the knee, insomnia and unspecified indications. It is administered through oral route in the form of soft-gel capsule. The drug candidate acts by targeting cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) and is being developed based on TPM (tocopheryl phosphate mixture) technology.
Avecho Biotechnology overview
Avecho Biotechnology (Avecho) is a research-driven biotechnology firm that develops and commercializes human and animal health products. The company’s product portfolio includes daptomycin, diclofenac gel, propofol injection, oxymorphone patch, oxycodone patch, tretinoin gel and transdermal opioid patches. Its products are used in various applications including injectable dosage forms, feed additives, oral dosage forms, and topical and transdermal dosage forms. Avecho also develops cannabinoid products in partnership with major drug manufacturers. The company markets products under Vital ET, Voveran, Instanac, and TPM brand names. It has business presence in Australia, India, Switzerland, and the US. Avecho is headquartered in Clayton, Victoria, Australia.
For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
